CHICAGO — Belantamab mafodotin monotherapy did not significantly extend PFS compared with the combination of pomalidomide and dexamethasone among adults with relapsed or refractory multiple myeloma, phase 3 study results showed. However, data from the randomized trial presented at ASCO Annual Meeting suggest that single-agent treatment with belantamab mafodotin (Blenrep, GSK) may have
/PRNewswire/ The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in Europe and Australia,.
Credit: Dana-Farber Cancer Institute
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
In a study posted online today by the
New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer. These rates, and the duration of the responses, are significantly better than those produced by currently available therapies for patients with multiple relapses, according to investigators.